LAVA Medtech Acquisition Corp. Announces Closing of $115 Million Initial Public Offering Including Full Exercise of the Over-Allotment Option
29 Octobre 2021 - 5:38PM
LAVA Medtech Acquisition Corp. (the “Company”)
today announced the closing of its initial public offering of
11,500,000 units at a price of $10.00 per unit, including 1,500,000
units pursuant to the full exercise of the underwriters’
over-allotment option. The offering was priced at $10.00 per unit,
resulting in gross proceeds of $115,000,000. The Company’s units
commenced trading on the Nasdaq Global Market (“Nasdaq”) on October
27, 2021, under the ticker symbol “LVACU.”
Each unit sold in the offering consists of one
share of the Company’s Class A common stock and one-half of one
redeemable warrant, each whole warrant entitling the holder thereof
to purchase one share of Class A common stock at a price of $11.50
per share. Only whole warrants are exercisable and will trade. Once
the securities comprising the units begin separate trading, the
shares of Class A common stock and warrants are expected to be
listed on the Nasdaq under the symbols “LVAC” and “LVACW,”
respectively.
The Company is a newly incorporated blank check
company formed for the purpose of effecting a merger, capital stock
exchange, asset acquisition, stock purchase, reorganization or
similar business combination with one or more businesses.
The Company is led by Chairman Richard “Dick”
Emmitt; Chief Executive Officer Anthony Natale, M.D.; President
Gerry Brunk; Executive Vice President Daniel Hetu, M.D.; and Chief
Financial Officer Vasco Larcina. In addition to Dr. Natale and
Messrs. Brunk and Emmitt, the Company’s Board of Directors includes
Peter van der Velden and Fritz LaPorte.
RBC Capital Markets served as the sole
book-running manager of the offering.
The initial public offering was made only by
means of a prospectus. Copies of the prospectus relating to the
offering may be obtained from RBC Capital Markets, LLC, 200 Vesey
Street, 8th Floor, New York, NY 10281-8098; Attention: Equity
Syndicate; by telephone at 877-822-4089 or by email at
equityprospectus@rbccm.com.
A registration statement relating to these
securities was filed with the Securities and Exchange Commission
(the “SEC”) on October 15, 2021, and was declared effective on
October 26, 2021. This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
Cautionary Note Concerning
Forward-Looking Statements
This press release contains statements that
constitute “forward-looking statements,” including with respect to
the proposed initial public offering and the anticipated use of the
net proceeds. No assurance can be given that the offering discussed
above will be completed on the terms described, or at all, or that
the net proceeds of the offering will be used as indicated.
Forward-looking statements are subject to numerous conditions, many
of which are beyond the control of the Company, including those set
forth in the Risk Factors section of the Company’s registration
statement and preliminary prospectus for the Company’s offering
filed with the SEC. Copies of these documents are available on the
SEC’s website, www.sec.gov. The Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release, except as required by law.
Contact:
LAVA Medtech Acquisition Corp.Anthony
NataleChief Executive Officer Tel: (617) 600 - 4054Email:
info@lavamedtechacquisition.comWebsite:
www.lavamedtechacquisition.com
LAVA Medtech Acquisition (NASDAQ:LVAC)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
LAVA Medtech Acquisition (NASDAQ:LVAC)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024